AR106296A1 - Tetrahidropiranilsulfonas sustituidas con pirazolilo - Google Patents
Tetrahidropiranilsulfonas sustituidas con pirazoliloInfo
- Publication number
- AR106296A1 AR106296A1 ARP160103077A ARP160103077A AR106296A1 AR 106296 A1 AR106296 A1 AR 106296A1 AR P160103077 A ARP160103077 A AR P160103077A AR P160103077 A ARP160103077 A AR P160103077A AR 106296 A1 AR106296 A1 AR 106296A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- cycloalkyl
- aryl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Tetrahidropiranilsulfonas sustituidas con pirazolilo como bloqueadores de los canales de calcio dependientes de voltaje, a composiciones farmacéuticas que contienen estos compuestos y también a estos compuestos para utilizar en el tratamiento y/o profilaxis del dolor y de otras enfermedades y/o trastornos. Reivindicación 1: Un compuesto de fórmula general (1), donde R¹ se selecciona del grupo que consiste en H o alquilo C₁₋₆; R² se selecciona del grupo que consiste en H o alquilo C₁₋₆; R³ es H; R⁴ representa L-R⁵, donde L es un enlace, CH₂, C(CH₃)₂, O ó S(=O)₂ y R⁵ se selecciona del grupo que consiste en alquilo C₁₋₆, cicloalquilo C₃₋₆ o heterociclilo de 3 a 7 miembros, donde dicho heterociclilo de 3 a 7 miembros se caracteriza porque contiene un heteroátomo o grupo de heteroátomos, seleccionados entre O, NH, N(CH₃), S(=O) y S(=O)₂; donde dicho alquilo C₁₋₆ está sin sustituir o sustituido con uno o dos o tres o cuatro sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, CN, OH, OCH₃, OCFH₂, OCHF₂, OCF₃, S(=O)₂CH₃, S(=O)₂CHF₂, S(=O)₂CF₃, S(=O)₂CH(CH₃)₂, S(=O)₂(c-propilo), NH₂, NH(CH₃), N(CH₃)₂, C(=O)NH₂, C(=O)NH(CH₃) y C(=O)N(CH₃)₂; y donde dicho cicloalquilo C₃₋₆ o dicho heterociclilo de 3 a 7 miembros está sin sustituir o sustituido con uno o dos o tres o cuatro sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, CN, CH₃, CFH₂, CHF₂, CF₃, =O, OH, OCH₃, CH₂OH, CH₂OCH₃, OCFH₂, OCHF₂, OCF₃, S(=O)₂CH₃, S(=O)₂CHF₂, S(=O)₂CF₃, S(=O)₂CH(CH₃)₂, S(=O)₂(c-propilo), NH₂, NH(CH₃), N(CH₃)₂, C(=O)NH₂, C(=O)NH(CH₃) y C(=O)N(CH₃)₂; Ar¹ representa arilo o heteroarilo, donde dicho arilo o dicho heteroarilo está sustituido con cero o uno o dos o tres sustituyentes R⁷, donde cada R⁷ se selecciona independientemente del grupo que consiste en F; Cl; Br; I; NO₂; CN; alquilo C₁₋₆; CF₃; CF₂H; CFH₂; CF₂Cl; CFCl₂; C(O)-H; C(O)-alquilo C₁₋₆; C(O)-OH; C(O)-O-alquilo C₁₋₆; C(O)-N(H)(OH); C(O)-NH₂; C(O)-N(H)(alquilo C₁₋₆); C(O)-N(alquilo C₁₋₆)₂; C(=N-OH)-H; C(=N-OH)-alquilo C₁₋₆; C(=N-O-alquil C₁₋₆)-H; C(=N-O-alquil C₁₋₆)-alquilo C₁₋₆; OH; OCF₃; OCF₂H; OCFH₂; OCF₂Cl; OCFCl₂; O-alquilo C₁₋₆; O-C(O)-alquilo C₁₋₆; O-C(O)-O-alquilo C₁₋₆; O-(CO)-N(H)(alquilo C₁₋₆); O-C(O)-N(alquilo C₁₋₆)₂; O-S(O)₂-alquilo C₁₋₆; O-S(O)₂-OH; O-S(O)₂-O-alquilo C₁₋₆; O-S(O)₂-NH₂; O-S(O)₂-N(H)(alquilo C₁₋₆); O-S(O)₂-N(alquilo C₁₋₆)₂; NH₂; N(H)(alquilo C₁₋₆); N(alquilo C₁₋₆)₂; N(R¹³)-C(O)-alquilo C₁₋₆; N(R¹³)-C(O)-O-alquilo C₁₋₆; N(R¹³)-C(O)-NH₂; N(R¹³)-C(O)-N(H)(alquilo C₁₋₆); N(R¹³)-C(O)-N(alquilo C₁₋₆)₂; N(R¹³)-S(O)₂OH; N(R¹³)-S(O)₂-alquilo C₁₋₆; N(R¹³)-S(O)₂-O-alquilo C₁₋₆; N(R¹³)-S(O)₂-NH₂; N(R¹³)-S(O)₂-N(H)(alquilo C₁₋₆); N(R¹³)-S(O)₂N(alquilo C₁₋₆)₂; SH; SCF₃; SCF₂H; SCFH₂; SCF₂Cl; SCFCl₂; S-alquilo C₁₋₆; S(O)-alquilo C₁₋₆; S(O)₂-alquilo C₁₋₆; S(O)₂-OH; S(O)₂-O-alquilo C₁₋₆; S(O)₂-NH₂; S(O)₂-N(H)(alquilo C₁₋₆); S(O)₂-N(alquilo C₁₋₆)₂; cicloalquilo C₃₋₆; heterociclilo de 3 a 7 miembros; arilo; heteroarilo; O-cicloalquilo C₃₋₆; O-(heterociclilo de 3 a 7 miembros); O-arilo; O-heteroarilo; N(R¹³)-cicloalquilo C₃₋₆; N(R¹³)-(heterociclilo de 3 a 7 miembros); N(R¹³)-arilo; N(R¹³)-heteroarilo; C(O)-cicloalquilo C₃₋₆; C(O)-(heterociclilo de 3 a 7 miembros); C(O)-arilo; C(O)-heteroarilo; S(O)₂-cicloalquilo C₃₋₆; S(O)₂-(heterociclilo de 3 a 7 miembros); S(O)₂-arilo; S(O)₂-heteroarilo; S(O)N(R¹³)-cicloalquilo C₃₋₆; S(O)N(R¹³)-(heterociclilo de 3 a 7 miembros); S(O)N(R¹³)-arilo y S(O)N(R¹³)-heteroarilo, donde R¹³ representa H o alquilo C₁₋₆; con la condición de que el compuesto de fórmula general (1) no sea 5-(trifluoro-metil)-3-[4-metil-4-[[3-(trifluorometil)fenil]sulfonil]-tetrahidro-piran-2-il]-1H-pirazol opcionalmente en forma de un estereoisómero único o una mezcla de estereoisómeros, en forma del compuesto libre y/o una sal fisiológicamente aceptable y/o un solvato fisiológicamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15002879 | 2015-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106296A1 true AR106296A1 (es) | 2018-01-03 |
Family
ID=54293014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103077A AR106296A1 (es) | 2015-10-08 | 2016-10-07 | Tetrahidropiranilsulfonas sustituidas con pirazolilo |
Country Status (12)
Country | Link |
---|---|
US (1) | US10106530B2 (es) |
EP (2) | EP3617203A1 (es) |
JP (1) | JP2018530567A (es) |
CN (1) | CN108368092A (es) |
AR (1) | AR106296A1 (es) |
AU (1) | AU2016336776A1 (es) |
BR (1) | BR112018007006A2 (es) |
CA (1) | CA3001044A1 (es) |
HK (1) | HK1258456A1 (es) |
MX (1) | MX2018004220A (es) |
TW (1) | TW201718557A (es) |
WO (1) | WO2017059965A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR100073A1 (es) | 2014-04-14 | 2016-09-07 | Gruenenthal Gmbh | Sulfonas heterocíclicas sustituidas con heteroarilos |
BR112016023926A2 (pt) | 2014-04-14 | 2017-08-15 | Gruenenthal Gmbh | heterociclil sulfonas substituídas por aril |
TW201726128A (zh) | 2015-10-08 | 2017-08-01 | 歌林達有限公司 | 經吡唑基取代之四氫哌喃基碸 |
AU2018313850B2 (en) | 2017-08-09 | 2022-12-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
SI3676297T1 (sl) * | 2017-09-01 | 2023-12-29 | Denali Therapeutics Inc. | Spojine, sestavki in postopki |
SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
WO2021038586A1 (en) * | 2019-08-29 | 2021-03-04 | Keminntek Laboratories | Improved process for the preparation of tezacaftor intermediate |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006522130A (ja) * | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール |
US7799822B2 (en) * | 2005-12-21 | 2010-09-21 | Vertex Pharmaceuticals Incorporated | Phenyl sulfonamides as modulators of ion channels |
WO2007125398A2 (en) | 2006-04-27 | 2007-11-08 | Pfizer Japan Inc. | : sulfonamide compounds as antagonists of the n-type calcium channel |
US8193194B2 (en) * | 2007-05-25 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
CA2771710A1 (en) | 2009-09-18 | 2011-03-24 | Zalicus Pharmaceuticals Ltd. | Aryl sulphone derivatives as calcium channel blockers |
JP6262732B2 (ja) * | 2012-08-16 | 2018-01-17 | ヤンセン ファーマシューティカ エヌ.ベー. | N型カルシウムチャネル遮断剤としての置換ピラゾール |
PE20151140A1 (es) * | 2012-08-16 | 2015-08-07 | Janssen Pharmaceutica Nv | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n |
TW201416348A (zh) * | 2012-08-29 | 2014-05-01 | Gruenenthal Chemie | 以氟甲基取代之吡咯甲醯胺 |
AR100073A1 (es) | 2014-04-14 | 2016-09-07 | Gruenenthal Gmbh | Sulfonas heterocíclicas sustituidas con heteroarilos |
BR112016023926A2 (pt) * | 2014-04-14 | 2017-08-15 | Gruenenthal Gmbh | heterociclil sulfonas substituídas por aril |
TW201726128A (zh) | 2015-10-08 | 2017-08-01 | 歌林達有限公司 | 經吡唑基取代之四氫哌喃基碸 |
-
2016
- 2016-10-06 TW TW105132385A patent/TW201718557A/zh unknown
- 2016-10-07 EP EP19198302.2A patent/EP3617203A1/en not_active Withdrawn
- 2016-10-07 AU AU2016336776A patent/AU2016336776A1/en not_active Abandoned
- 2016-10-07 CN CN201680057963.2A patent/CN108368092A/zh active Pending
- 2016-10-07 AR ARP160103077A patent/AR106296A1/es unknown
- 2016-10-07 CA CA3001044A patent/CA3001044A1/en not_active Abandoned
- 2016-10-07 BR BR112018007006A patent/BR112018007006A2/pt not_active Application Discontinuation
- 2016-10-07 MX MX2018004220A patent/MX2018004220A/es unknown
- 2016-10-07 US US15/287,947 patent/US10106530B2/en not_active Expired - Fee Related
- 2016-10-07 JP JP2018517883A patent/JP2018530567A/ja not_active Withdrawn
- 2016-10-07 EP EP16781291.6A patent/EP3359534A1/en not_active Withdrawn
- 2016-10-07 WO PCT/EP2016/025107 patent/WO2017059965A1/en active Application Filing
-
2019
- 2019-01-16 HK HK19100761.6A patent/HK1258456A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3359534A1 (en) | 2018-08-15 |
WO2017059965A1 (en) | 2017-04-13 |
US20170101397A1 (en) | 2017-04-13 |
TW201718557A (zh) | 2017-06-01 |
EP3617203A1 (en) | 2020-03-04 |
CA3001044A1 (en) | 2017-04-13 |
JP2018530567A (ja) | 2018-10-18 |
CN108368092A (zh) | 2018-08-03 |
AU2016336776A1 (en) | 2018-05-24 |
MX2018004220A (es) | 2018-11-09 |
US10106530B2 (en) | 2018-10-23 |
BR112018007006A2 (pt) | 2018-10-16 |
HK1258456A1 (zh) | 2019-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106296A1 (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo | |
AR100073A1 (es) | Sulfonas heterocíclicas sustituidas con heteroarilos | |
CO2022004594A2 (es) | Oxinitruro de piridina, método para su preparación y uso de este | |
AR106295A1 (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo | |
AR097325A1 (es) | Pirroles anillados | |
AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
EA201792421A1 (ru) | Амидозамещенные производные циклогексана | |
AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k | |
AR110088A1 (es) | Inhibidores de magl | |
AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
AR092279A1 (es) | Pirrol carboxamidas fluorometilo sustituidas | |
AR108906A1 (es) | Heterociclos de biarilmetilo | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
AR094735A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4 | |
AR101196A1 (es) | Compuestos de pirimidina sustituidos | |
EA201590022A1 (ru) | Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса | |
EA202090448A1 (ru) | Дигидрооксадиазиноны | |
CY1123955T1 (el) | [8-(φαινυλοσουλφονυλο)-3,8-διαζαδικυκλο[3.2.1]οκτ-3-υλο](1η-1,2,3-τριαζολο-4-υλο)μεθανονες | |
AR084505A1 (es) | Derivados de 5-metil-1-(naftalen-2-il)-1h-pirazol | |
RU2016131363A (ru) | ПРОИЗВОДНЫЕ АРИЛСУЛЬТАМА В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРФАННОГО РЕЦЕПТОРА γ, СВЯЗАННОГО С РЕТИНОЕВОЙ КИСЛОТОЙ | |
AR094412A1 (es) | Carboxamidas basadas en pirazolilo i |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |